Breaking News

Tweet TWEET

Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014

Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference
Call on February 27, 2014

BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, today announced that it will host a conference call with members of
Amarin senior management to discuss the company's fourth quarter and year-end
2013 financial results and provide an operational update on Thursday, February
27, 2014, at 4:30 p.m. ET. The conference call will follow the anticipated
release of the company's fourth quarter and year-end 2013 financial results
earlier that day.

The conference call can be heard live via the investor relations section of
the company's website at www.amarincorp.com, or via telephone by dialing
877-407-8033 within the United States or 201-689-8033 from outside the United
States. A replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial 877-660-6853
(inside the United States) or 201-612-7415 (outside the United States). A
replay of the call will also be available through the company's website
shortly after the call. For both dial-in numbers please use conference ID
13576006.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA and is available by prescription. For more
information about Vascepa visit www.vascepa.com. For more information about
Amarin visit www.amarincorp.com.

Availability of other information about Amarin

Investors and others should note that we communicate with our investors and
the public using our company website (www.amarincorp.com), our investor
relations website (http://www.amarincorp.com/investor-splash.html), including
but not limited to investor presentations and investor FAQs,Securities and
Exchange Commissionfilings, press releases, public conference calls and
webcasts. The information that we post on these channels and websites could be
deemed to be material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information that we post
on these channels, including our investor relations website, on a regular
basis. This list of channels may be updated from time to time on our investor
relations website and may include social media channels. The contents of our
website or these channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by reference in
any filing under the Securities Act of 1933.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.